Aligos Therapeutics

ALGS

Biotechnology · Healthcare

Price

$5.74

-0.01 (-0.17%)

Market Cap

$35.5M

Exchange

NASDAQ Global Select

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Share count falling — buybacks

−75.2% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 39.9M (2021) → 9.9M (2025)

Aligos Therapeutics is a clinical-stage biotechnology company focused on developing treatments for chronic liver diseases and certain viral infections. Its main targets include chronic hepatitis B, a viral liver disease affecting hundreds of millions of people worldwide, as well as nonalcoholic steatohepatitis (NASH), a serious form of liver disease with no approved treatments. The company does not yet sell any approved drugs and is entirely in the research and testing phase.

Aligos makes no meaningful product revenue today. It funds its operations primarily through cash raised from investors and occasional research partnerships or licensing deals with larger pharmaceutical companies. Based in San Francisco, it is a small company with a market cap near zero, reflecting the high failure rate of early-stage drug development. The central risk is that its pipeline drugs may fail in clinical trials, which would leave the company without a path to revenue and force it to raise more capital or shut down programs entirely.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+810.0% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

-143.2% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$69M/ year

→ Flat (-1% vs prior year)

>1,000% of revenue

176.5x the sector average (18%)

Steady R&D investment year-over-year

Insider Activity

22.5%ownership

Insiders own a meaningful stake in the company

Cash Runway

~7 months

$55M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Revenue accelerating

Aligos Therapeutics grew revenue 810% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Operating Margin

-951.6%

Losing money on operations — -951.6%

ROCE

-75.9%

Weak — -75.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+43.9%

Fast-growing sales (43.9% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

-1810.5%

Burning cash (-1810.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.12

Conservative — low debt load (0.12)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial